← All trials
NCT04054752
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 16, 2019
- Primary completion
- May 19, 2024
- Completion date
- May 19, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- National Cancer Institute (NCI)Overall official - principal investigator
- NeoImmuneTech, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.